IP Library Granted Patent US 8,492,354
Granted Patent B2
US 8,492,354 · App. 13/295,227 · Granted Jul 23, 2013

Antibacterial aminoglycoside analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,492,354
App. No.
13/295,227
Granted
Jul 23, 2013
Kind
B2
Abstract

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q 1 , Q 2 , Q 3 , R 11 and R 12 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Claims (44)

1. A compound having the following structure (I):

or a stereoisomer or pharmaceutically acceptable salt thereof,

wherein:

Q 1 is alkyl optionally substituted with hydroxyl or amino,

Q 2 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —C(═NH)NR 7 R 8 ,

Q 3 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —C(═NH)NR 7 R 8 ,

each R 4 , R 5 , R 7 , R 8 and R 11 is, independently, hydrogen or C 1 -C 6 alkyl optionally substituted with one or more halogen, hydroxyl or amino;

each R 6 is, independently, hydrogen, halogen, hydroxyl, amino or C 1 -C 6 alkyl;

or R 4 and R 5 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R 5 and one R 6 together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms, or R 4 and one R 6 together with the atoms to which they are attached can form a carbocyclic ring having from 3 to 6 ring atoms, or R 7 and R 8 together with the atom to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms;

each R 9 and R 12 is, independently, hydrogen, hydroxyl, amino or C 1 -C 6 alkyl optionally substituted with one or more halogen, hydroxyl or amino;

each R 10 is, independently, hydrogen, halogen, hydroxyl, amino or C 1 -C 6 alkyl;

or R 9 and one R 10 together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms; and

each n is, independently, an integer from 0 to 4, and

wherein (i) at least one of Q 2 and Q 3 is other than hydrogen, and (ii) Q 1 is not ethyl or —C(═O)CH 3 .

2. A compound of claim 1 wherein Q 2 is other than hydrogen.

3. A compound of claim 2 wherein Q 3 is hydrogen.

4. A compound of claim 2 wherein Q 2 is optionally substituted alkyl.

5. A compound of claim 4 wherein Q 2 is substituted with hydroxyl or amino.

6. A compound of claim 1 wherein R 11 is hydrogen.

7. A compound of claim 1 wherein each R 12 is methyl.

8. A pharmaceutical composition comprising a compound of claim 1 , or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

9. A method of treating a bacterial infection in a mammal in need thereof, comprising administering to the mammal an effective amount of a compound of claim 1 or a composition of claim 8 .

10. A compound having the following structure (I):

or a stereoisomer or pharmaceutically acceptable salt thereof,

wherein:

Q 1 is

Q 2 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —C(═NH)NR 7 R 8 ,

Q 3 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —C(═NH)NR 7 R 8 ,

each R 4 , R 5 , R 7 , R 8 and R 11 is, independently, hydrogen or C 1 -C 6 alkyl optionally substituted with one or more halogen, hydroxyl or amino;

each R 6 is, independently, hydrogen, halogen, hydroxyl, amino or C 1 -C 6 alkyl;

or R 4 and R 5 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R 5 and one R 6 together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms, or R 4 and one R 6 together with the atoms to which they are attached can form a carbocyclic ring having from 3 to 6 ring atoms, or R 7 and R 8 together with the atom to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms;

each R 9 and R 12 is, independently, hydrogen, hydroxyl, amino or C 1 -C 6 alkyl optionally substituted with one or more halogen, hydroxyl or amino;

each R 10 is, independently, hydrogen, halogen, hydroxyl, amino or C 1 -C 6 alkyl;

or R 9 and one R 10 together with the atoms to which they are attached can form a heterocyclic ring having from 3 to 6 ring atoms; and

each n is, independently, an integer from 0 to 4, and

wherein (i) at least one of Q 2 and Q 3 is other than hydrogen, and (ii) for Q 1 , R 5 and one R 6 together with the atoms to which they are attached form a heterocyclic ring having 3 ring atoms, or R 4 and one R 6 together with the atoms to which they are attached form a carbocyclic ring having 3 ring atoms, or R 9 and one R 10 together with the atoms to which they are attached form a heterocyclic ring having 3 ring atoms.

11. A compound of claim 10 wherein Q 2 is other than hydrogen.

12. A compound of claim 11 wherein Q 3 is hydrogen.

13. A compound of claim 11 wherein Q 2 is optionally substituted alkyl.

14. A compound of claim 13 wherein Q 2 is substituted with hydroxyl or amino.

15. A compound of claim 10 wherein R 11 is hydrogen.

16. A compound of claim 10 wherein each R 12 is methyl.

17. A pharmaceutical composition comprising a compound of claim 10 , or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

18. A method of treating a bacterial infection in a mammal in need thereof, comprising administering to the mammal an effective amount of a compound of claim 10 or a composition of claim 17 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2020
From: ACHAOGEN, INC.
To: CIPLA USA, INC.
Reel/Frame 052159/0853 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 19, 2019
From: ACHAOGEN, INC.
To: SILICON VALLEY BANK
Reel/Frame 048947/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2012
From: DOZZO, PAOLA; GOLDBLUM, ADAM AARON; AGGEN, JAMES BRADLEY; LINSELL, MARTIN SHERINGHAM
To: ACHAOGEN, INC.
Reel/Frame 027693/0625 →